Study Shows Caris Molecular Profiling Could Allow Use of PD-1 Inhibitors In Breast Cancer

Study Shows Caris Molecular Profiling Could Allow Use of PD-1 Inhibitors In Breast Cancer
shutterstock_146164970Caris Life Sciences has announced the publication of a scientific study whereby the company’s panomic, comprehensive tumor profiling service, Caris Molecular Intelligence, was successfully used to explore the utility of programmed cell death protein 1 (PD-1) and its ligand, PD-L1 in a variety of solid tumors, including breast cancer. The study, titled Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type and published in the Cancer Epidemiology, Biomarkers & Prevention journal, showed that PD-1-positive tumor infiltrating lymphocytes (TILs) were not common in some types of cancer, but were observed in 70% of triple-negative breast cancer, a type of breast cancer that does not express estrogen receptors, progesterone receptors, or large amounts of HER2/neu protein. Furthermore, PD-1-positive TILs were observed in 73% of bladder cancers, 77% of microsatellite instability high (MSI-H) colon cancers, 75% of non-small cell lung cancers, 86% of endometrial cancer, and 93% of ovarian cancer. The presence of PD-1 positive TILs was
Subscribe or to access all post and page content.